BioMed Research International / 2014 / Article / Tab 1 / Research Article
Synchronous and Metachronous Breast Malignancies: A Cross-Sectional Retrospective Study and Review of the Literature Table 1 Population characteristics: data is presented, where appropriate, as mean value (±standard deviation) and one way
, median value (interquartile range) and Kruskall-Wallis
, or prevalence and chi-square test.
UBC 1st MBC 2nd MBC 1st SBC 2nd SBC
Women age
58.71 (±15.47) 56.54 (±13.68) 64.38 (±13.41) 64.94 (±14.72) 65.25 (±14.15) <0.05 BMI
26.74 (±5.24) 26.17 (±6.14) 25.18 (±4.64) 0.556 Time interval between 1st and 2nd MBC
72 (40–120) N/A Follow-up
79 (70–85) 97 (82–120) 66 (23–82) 79 (72–90) <0.05 Tobacco smoke 2.46% (13/528) 0% (0/39) 0% (0/16) 0.500 Familial history 0.95% (5/528) 0% (0/39) 6.25% (1/16) 0.094 Mode of diagnosis Unknown 4.55% (24/528) 2.56% (1/39) 2.5% (1/40) 0% (0/16) 0% (0/16) 0.709 Objective examination 46.78% (247/528) 69.23% (27/39) 30% (12/40) 31.25% (5/16) 12.5% (2/16) <0.05 Mammography 36.17% (191/528) 20.51% (8/39) 57.5% (23/40) 43.75% (7/16) 62.5% (10/16) <0.05 Ultrasound 12.5% (66/528) 7.69% (3/39) 10% (4/40) 25% (4/16) 25% (4/16) 0.236 Radiotherapy 56.44% (241/427) 64.86% (24/37) 46.67% (7/15) 0.442 Chemotherapy 45.88% (195/425) 47.22% (17/36) 57.14% (8/14) 0.703 Hormonal therapy 70.85% (299/422) 80.56% (29/36) 100% (14/14) <0.05 Tamoxifen therapy 44.13% (233/528) 53.85% (21/39) 62.5% (10/16) 0.187